Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Autor:	Mormino EC; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. bmormino@nmr.mgh.harvard.edu., Betensky RA; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Hedden T; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Schultz AP; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Ward A; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Huijbers W; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Rentz DM; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Johnson KA; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Sperling RA; From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jazyk:	angličtina
Zdroj:	Neurology [Neurology] 2014 May 20; Vol. 82 (20), pp. 1760-7. Date of Electronic Publication: 2014 Apr 18.
DOI:	10.1212/WNL.0000000000000431
Abstrakt:	Objective: To examine whether β-amyloid (Aβ) and APOE ε4 status independently contribute or interact to influence longitudinal cognitive decline in clinically normal older individuals (CN). Methods: Data from 490 CNs were aggregated across 3 observational cohort studies (Harvard Aging Brain Study, Alzheimer's Disease Neuroimaging Initiative, and Australian Imaging Biomarkers and Lifestyle Study of Ageing; median age = 75.0 years, 255 female), and the contributions of APOE ε4 and Aβ on longitudinal change over a median of 1.49 years were examined. Cognitive decline was assessed with the Mini-Mental State Examination (MMSE) and Logical Memory (immediate and delayed recall scores). Results: High Aβ participants were more likely to be APOE ε4+ than low Aβ participants. CNs who were both high Aβ and APOE ε4+ showed greater decline in Logical Memory immediate recall (p < 0.087), Logical Memory delayed recall (p < 0.024), and MMSE (p < 0.034) compared to all other groups (low Aβ/APOE ε4-, low Aβ/APOE ε4+, and high Aβ/APOE ε4-). No other pairwise contrast was significant for any cognitive measure. Conclusions: Clinically normal individuals who are APOE ε4+ and have high Aβ showed the highest cognitive decline. These results suggest that Aβ and APOE ε4 are not redundant contributors of decline in aging but rather interact to promote decline during the short follow-up period examined in this study. Longer follow-up periods will be essential to fully elucidate the influence of Alzheimer disease risk factors on cognitive decline in aging. (© 2014 American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu